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The impact of COVID-19 on healthcare
delivery for people who use opioids: a
scoping review
Karen Alexander1* , Monika Pogorzelska-Maziarz1, Angela Gerolamo1, Nadia Hassen1, Erin L. Kelly2 and
Kristin L. Rising3

Abstract
Research objective: The COVID-19 pandemic disrupted healthcare delivery worldwide with likely negative effects
on people who use opioids (PWUO). This scoping review of the original research literature describes the impact of
the COVID-19 pandemic on healthcare delivery for PWUO and identifies gaps in the literature.
Methods: This scoping review of the original research literature maps the available knowledge regarding the
impact of the COVID-19 pandemic on healthcare delivery for PWUO. We utilized the methodology developed by
the Joanna Briggs Institute for scoping reviews, and content analyses methodology to characterize the current state
of the literature.
Results: Of the 14 included studies, administrative database (n = 11), cross-sectional (n = 1) or qualitative (n = 2)
studies demonstrated service gaps (n = 7), patient/provider experiences (n = 3), and patient outcomes for PWUO
(n = 4). In March 2020, healthcare utilization dropped quickly, sharply increasing only for reasons of opioid overdose
by May 2020. Service gaps existed in accessing treatment for new patients during the pandemic due to capacity
and infrastructure limits. Physicians reported difficulty referring patients to begin an outpatient opioid treatment
program due to increased restrictions in capacity and infrastructure. Patients also reported uncertainty about
accessing outpatient treatment, but that telehealth initiation of buprenorphine increased access to treatment from
home. Disproportionate increases in overdose rates among African Americans were reported in two studies, with
differences by race and gender not examined in most studies. Fatal overdoses increased 60% in African Americans
during the pandemic, while fatal overdoses in Non-Hispanic White individuals decreased.
Conclusions: In summary, this beginning evidence demonstrates that despite early reluctance to use the
healthcare system, opioid overdose-related use of healthcare increased throughout the pandemic. Service delivery
for medications to treat OUD remained at or above pre-pandemic levels, indicating the ability of telehealth to meet
demand. Yet, racial disparities that existed pre-pandemic for PWUO are intensifying, and targeted intervention for
high-risk groups is warranted to prevent further mortality. As the pandemic progresses, future research must focus
on identifying and supporting subgroups of PWUO who are at heightened risk for experiencing negative outcomes
and lack of access to care.
Keywords: Opioid use, Healthcare delivery, Pandemic
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Background
Over 58 million people used opioids in 2019, and
500,000 drug-related overdoses occurred, mostly attributable to opioids [1]. Recent work has demonstrated disparities in the rate of opioid-related overdoses in the
United States (US) among certain subgroups of the
population [2]. Although non-Hispanic white men comprise the largest percentage of overdose deaths, fatal
overdoses are increasing at a significantly higher rate
among racial minority groups as compared to white men
[3]. Geographically, the northeastern US is seeing the
highest increase in overdose fatalities with an average increase of 200% in the mid-Atlantic and New England
states from 1999 to 2017 [3].
The delivery of quality and timely healthcare to people
who use opioids (PWUO) can prevent opioid related
mortality and morbidity through harm reduction strategies and medications to treat opioid use disorder
(OUD) [4]. Methadone is the most frequently prescribed
medication for OUD (MOUD) and is administered daily
in an outpatient setting, but with significant thresholds
for entering and maintaining treatment, such as waiting
lists, frequent urine toxicology, and timed dosing of
medication dispensing [5]. Buprenorphine is the second
most used MOUD and can be prescribed in an emergency department (ED), Office-based Opioid Treatment
(OBOT) or an outpatient Opioid Treatment Program
(OTP) [6]. Alongside pharmacologic treatments, psychotherapy, housing support and job training are highly recommended for people in recovery [4].
The care received in these differing settings is influenced greatly by federal and local policies, which have
improved greatly in recent years. For example, The SUPPORT Act of 2018 requires OBOT and OTP to be covered by Medicaid and Medicare andthe Comprehensive
Addiction and Recovery Act in 2016 made provisions for
increased numbers of healthcare providers (including
physician’s assistants, and nurse practitioners) to prescribe buprenorphin [7]. The result is an increasing
number of patients enrolled in treatment in the last 5
years, especially in rural areas [8, 9].
Until recently, healthcare providers were required to
perform in-person physicals prior to prescribing any
MOUD under the Ryan Haight Act [7]. The Ryan Haight
Act was established to prevent illicit online pharmacies
from adding to the opioid epidemic. Federal regulations
also placed strict dosing limits on MOUD at OTP with
requirements for daily or weekly follow-up visits in early
stages of treatment [10]. However, these guidelines surrounding the treatment of OUD were altered during the
coronavirus-2019 (COVID-19) pandemic.
Due to the nature of the COVID-19 public health crisis, stay-at-home orders were in place globally by March
2020. PWUO then faced restrictions to in-person
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treatment intake, transportation problems for attending
their daily dosing appointments, and technology driven
limitations in accessing psychotherapy sessions. Fortunately, federal guidance released on March 16th, 2020 by
the Substance Abuse and Mental Health Association
(SAMHSA) allowed providers to prescribe buprenorphine without an in-person physical. Barriers to telehealth prescribing of buprenorphine were suspended
under a provision within the Ryan Haight Act for public
health emergencies. In addition, while methadone induction still required in-person intake appointments, methadone could be prescribed in 14- and 28- day take-home
options for patients demonstrating adequate adherence
to treatment. The policy changes to health care delivery
for PWUO during the COVID-19 pandemic are summarized in Fig. 1.
It is evident from prior work that people who use substances are at greater risk of COVID-19 related disease
[11], and that substance use overall has increased substantially during the pandemic [12]. PWUO face increased complexity in managing their health which may
have exacerbated their existing marginalization [13].
While previous reviews have examined the intersection
of substance use and COVID-19, there is a gap in evidence regarding changes in healthcare delivery for
PWUO during the pandemic.
As the pandemic continues, it is important to explore
how healthcare delivery can best support the provision
of safe and effective care for PWUO. To fill this gap, we
conducted a scoping review to assess the answer to this
question: What evidence exists regarding the intersection of the COVID-19 pandemic and health care delivery
for PWUO?

Methods
Data sources and search strategy

Before the study began, we determined the objective of
the study, the research question, inclusion criteria, and
method. With the assistance of a medical librarian, the
database search included English language articles within
3 databases using a defined search strategy. PubMed, the
Cumulative Index for Nursing and Allied Health Literature (CINAHL), and OVID Medline were searched,
without restricting the date of publication using the
terms: (Coronavirus OR COVID) AND (Opioid OR
methadone OR Buprenorphine OR suboxone OR opiate)
AND (outcome OR overdose OR emergency OR health).
No date restrictions were placed as it was presumed all
studies that were published using the terms COVID or
Coronavirus would be published after January 2020. The
search term list was compiled by study team members
(K.A., N.H). The five-stage process outlined by Arksey
and O’Malley of the Joanna Briggs Institute was used to
conduct the scoping review: 1) identify the research
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Fig. 1 SAMHSA guidance affecting healthcare delivery for PWUO after March 16th, 2020

question 2) identify the relevant studies 3) study selection 4) chart the data and 5) organize the results [14].
Screening strategy and inclusion criteria

Studies identified in the search process were screened by
title and abstract by two researchers (KA and NH) and
selected for full review if the studies: 1) reported opioidrelated health outcomes during the COVID-19 pandemic, 2) were written in English, and 3) were original,
empirical research conducted during the COVID-19
pandemic. Reviews, opinion articles and commentaries
were excluded. In addition, abstracts that reported on
health outcomes not related to opioid use (i.e. COVIDdisease mortality rates for PWUO) were excluded due to
the focus on opioid-related health care delivery. Duplicates were removed across the databases. The screening
process was refined prior to initiation by research team
members (K.A., N.H.), and any protocol irregularities
were discussed as an entire research team (K.A., NH,
AG, MPM). Articles that were eligible for full text review
were cross-checked by two additional reviewers, and disagreements were discussed until consensus was
achieved. The search process is reflected in a PRISMA
diagram (see Fig. 2).
Data extraction and synthesis

Data from articles that were eligible for full text review
were extracted into a table with the following headings:
author, year of publication, study location, intervention
(yes/no), study population, aim or purpose of the study,
methodology, outcome measures, and key findings. The
studies were reviewed with content analyses methodology [15] to categorize and interpret the findings across

the varying methodologies of the articles. Full text articles were reviewed and coded by three reviewers (KA,
AG, MPM), and agreement was achieved on
categorization. The research team identified broad categories for the articles: service delivery, patient/provider
experiences and patient outcomes. From these broad
categories, empirical results of the reviewed studies
allowed us to further refine these categories. While the
categories are likely not exhaustive of all concepts associated with healthcare delivery to PWOU in the time of
the COVID-19 pandemic, they provide a map or classification scheme to illustrate the types of evidence
available.

Results
The initial search was conducted in February 2021 and
yielded 278 peer-reviewed articles. After the removal of
duplicates, 47 review articles were immediately excluded;
210 opinion and commentaries were also excluded by
reading the abstracts. Three articles were excluded because they did not report on health outcomes related to
opioid use, but instead reported outcomes related to
COVID-19 disease in people who use substances. One
study [16] from Canada was excluded as as the policies
governing OTP and OBOT vary greatly from the US and
its inclusion would limit the generalizability of our review findings. Of the 18 articles reviewed in their full
text version for inclusion, 14 articles met the inclusion
criteria. Among the included studies, 79% (n = 11) were
descriptive studies utilizing administrative database or
medical chart review, one was a cross-sectional survey
and the remaining two were qualitative studies. Articles
were organized into three categories based on content:
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Fig. 2 PRISMA Diagram

service delivery (n = 7), provider/patient experiences
(n = 3), and patient outcomes (n = 4). Table 1 further describes the subthemes of the studies beneath the three
broader themes.
Studies represented outcomes from a cross-section of
the US healthcare system. The Eastern US (Massachusetts, New York City, New York, Philadelphia, Pennsylvania, Rhode Island) was most represented, with studies
also conducted in the Southern (Virginia, Kentucky,
Texas), Western (California and Oregon), and Midwestern US (Indiana). One qualitative study pulled data from
the Internet site Reddit, and therefore drew from an
international sample of Internet users. Studies primarily
reported on data from the first 3 months of the pandemic, though one study reported on data through October 2020 (see Fig. 3).
Service delivery

Seven studies (64%) examined service delivery using administrative datasets across different geographic regions
in the United States analyzing pandemic changes in
MOUD dispensing (n = 3) and ED/emergency medical
services (EMS) utilization (n = 4). Following the federal

guidance adjustments on March 16th, 2020, in-person
medication visits at OTP for MOUD declined 33% and
take-home medication (methadone or buprenorphine)
increased 97% in Oregon. Telehealth use for MOUD initiation and decreased restrictions on take-home medication had its intended effect of reducing crowding in
OTP clinics [17]. Using nationwide prescription tracking
data, buprenorphine was dispensed nationally at an expected rate through OBOT or OTP, but intramuscular
naloxone - an opioid reversal drug - was not [18]. Similarly, despite a significant decline in healthcare
utilization in Texas, the level of daily buprenorphine
prescriptions filled remained steady, again suggesting
that telehealth visits were able to meet the medication
prescribing needs of this population [19].
In Indiana, EMS providers recorded a 61% increase in
administration of naloxone to reverse suspected opioidrelated overdoses and a 47% increase in overdose-related
calls [20]. There were no changes in frequencies of overdose based on race or zip code. In Kentucky, a 17% increase in calls to EMS for overdose was reported, as well
as a 71% increase in patients refusing transport to the
hospital following an overdose EMS call [22]. The study
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Table 1 Categorization and descriptions of evidence
Theme/Authors/
Country

Study
Design(s)

Data Source(s)

Key findings

Service delivery (n = 7, 47%)
Prescriptions filled (n = 3)
McIlveen et al.
[17] (U.S./
Oregon)

Retrospectiv

Electronic medical record of outpatient OUD In-person medication dosing visits declined 33%, and take
treatment centers in Oregon
home medication increased 97% as intended.

Jones et al. [18]
(U.S./
Nationwide)

Retrospective IQVIA Total Patient Tracker
Database

Buprenorphine was dispensed at an expected rate, but
intramuscular naloxone was not.

Thornton et al.
[19] (U.S./Texas)

Retrospective Texas Prescription Monitoring Program
dataset

Filling of daily buprenorphine prescriptions remained steady.

EMSa and EDb utilization (n = 4)
Glober et al. [20] Retrospective EMS and coroner’s office record in Marion
(U.S./Indiana)
County, Indiana

47% increase in calls for overdose.

Holland et al.
[21] (U.S./
Nationwide)

Retrospective Center for Disease Control and Prevention’s
National Syndromic Surveillance Program

ED visits for reasons of opioid overdose were significantly
higher during the pandemic compared to 2019 rates.

Slavova et al.
[22] (U.S./
Kentucky)

Retrospective Kentucky State Ambulance Reporting
System

71% increase in refusal of transport to a hospital following an
overdose call to EMS. 50% increase in overdose calls involving
death at the scene.

Weiner et al. [23] Retrospective Massachusetts Ambulance Trip Information
(U.S./
System
Massachusetts)

After the stay-at-home order, most calls other than substance
use dropped, but substance related EMS calls increased
substantially.

Provider and patient experiences (n = 3, 20%)
Provider experiences (n = 2)
Caton et al. [24]
(U.S./California)

Crosssectional

Collins et al. [25] Qualitative
(U.S./Rhode
Island)

338 clinicians from 57 primary care clinics in 66% of clinics reported an easier time or an unchanged
California
difference in retention and engagement of clients during the
pandemic.
14 Emergency room healthcare providers

Barriers persist in connecting patients to outpatient treatment,
including capacity and infrastructure to use telehealth and,
COVID-test requirements as a barrier to accessing treatment.

300 posts of Reddit users related to COVID19 and opioid used

Concerns over less in-person access to OUD treatment facilities,
COVID-19 testing treatment requirements and exposure to
COVID were reported as an influence on motivation to seek
treatment.

Patient experiences (n = 1)
Krawczyk et al.
[26]
(International)

Qualitative

Patient outcomes (n = 5, 33%)
Overdose (n = 3)
Khatri et al. [27]
(U.S./
Pennsylvania)

Retrospective Philadelphia Dep Health Substance Use
Dashboard and Medical Examiner’s Office
Data

African Americans comprised 80% of overdose ED visits postpandemic, compared to 63% pre-pandemic.

Ochalek et al.
[28] (U.S./
Virginia)

Retrospective Electronic medical record of Virginia
Commonwealth University

During the pandemic, 2.5 patients were seen per day in the
emergency department with opioid overdose, compared to 1.4
patients per day pre-pandemic.

Rodda et al. [29] Retrospective Electronic medical records and medical
(U.S./California)
examiner records in San Francisco

Fatal overdoses significantly increased 60% in Non-Hispanic
Black patients post-COVID restrictions, overdoses in NonHispanic White patients decreased.

Retention in treatment (n = 1)
Tofighi et al. [30] Retrospective Bellevue Hospital (NYC) electronic medical
(U.S./New York)
record
a

Emergency Medical Services; bEmergency Department

56tg6
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Fig. 3 Distribution of Reported Data by Time Period and Country

also reported a 50% increase in overdose calls involving
a death at the scene. In Massachusetts, an initial decrease in all calls to EMS in March 2020, was followed
by a subsequent increase in substance-related EMS calls
by May 2020 [23]. The study also reported a high refusal
rate of hospital transportation in Massachusetts. Nationwide, while all-cause weekly ED visits decreased sharply
from March to May 2020, weekly ED visits for reasons
of opioid overdose were significantly higher during this
period when compared to March to May 2019 rates (n =
5502 vs 4168, p < .001).
Provider and patient experiences

Three studies (27%) described perceived treatment access from provider and patient perspectives in a crosssectional survey (n = 1) and qualitative (n = 2) studies. A
survey of primary care practices in California (n = 57)
found that the majority (91.2%) of OTP clinics adapted
their practices in response to COVID-19 with the most
common change being use of telehealth appointments
[24]. Clinics also reported prescribing buprenorphine for
longer durations since the onset of the pandemic and
67% of clinics reduced the frequency of urine drug
screenings for established patients [24]. Over half of
practices reported better retention and engagement with
patients in care using the partial telehealth service
model, including increased demand for counseling and
behavioral health services. ED physicians reported difficulty referring patients to begin community OTP due to
increased COVID-19 related restrictions in capacity and

infrastructure [25]. Finally, patients reported uncertainty
about accessing OTP due to possible exposure to
COVID-19 infection and increased COVID-19 related
restrictions in facilities [26]. Telehealth access to buprenorphine perceived by patients to increase access to
treatment; the increase in take-home medication was,
however, seen as risky by some patients, especially when
they were in the early days of treatment [26].
Patient outcomes

Four studies (36%) examined patient outcomes using either electronic health records or medical examiner data
in the US during the pandemic; outcomes included retention in treatment (n = 1), and overdose rates (n = 3).
In Philadelphia, fatal overdoses increased by 60% in
Non-Hispanic Black individuals when comparing April
to June 2020 to April to June 2019 data [27]. Virginia reported 80% of overdose visits to the ED were among
Black patients during the COVID-19 pandemic, compared to 63% pre-pandemic [28]. In San Francisco, fatal
overdoses in the ED nearly doubled during the pandemic
compared to pre-pandemic rates [29]. This contrasted
with a decrease in fatal overdoses among Non-Hispanic
White patients post-COVID restrictions in San Francisco [29].
One study examined treatment retention for new patients (n = 78) entering OUD treatment with a
buprenorphine-naloxone induction via telehealth in New
York City during the pandemic. At 8 weeks, 42 patients
remained in the program (53.8%), 21 were transitioned

Alexander et al. Substance Abuse Treatment, Prevention, and Policy

to a community treatment program (26.9%), 15 were lost
to follow-up (19.2%), and none were terminated from
care due to suspicions of diversion or misuse [30]. Telehealth was seen to be feasible, safe and as effective at
retaining patients in treatment with buprenorphine as
in-person visits.

Discussion
Healthcare services for PWUO quickly shifted at the onset of the COVID-19 pandemic to accommodate the
public health guidance set forth to reduce the spread of
COVID-19 while also incorporating changes in federal
and local policies for the administration of MOUD. In
this scoping review, we found that healthcare utilization
dropped quickly starting in March 2020, with the exception of care for opioid overdoses which sharply increased
beginning in May 2020. Service gaps in accessing treatment during the pandemic due to capacity and infrastructure limits were reported by patients and providers.
Disproportionate increases in overdose rates among
Black patients were reported in two studies, with differences by race and gender not reported in most studies.
This scoping review highlights the substantial unmet
need for connection to OUD treatment during the pandemic as rates of overdose and fatality rose substantially,
particularly for already marginalized populations. Overall, the evidence from this scoping review suggests that
greater flexibility in the provision of MOUD was necessary and beneficial for PWUO and merits support postpandemic.
During the beginning months of the pandemic, receipt
of MOUD continued at usual rates in three large studies,
demonstrating minimal disruption in providing treatment to patients through telehealth and take-at-home
medication protocols. However, barriers persisted in
connecting new patients to treatment with evidence
from patients and providers citing capacity and infrastructure limits [25, 26]. This may have inadvertently exacerbated race/ethnic treatment disparities, as White
PWUO were more likely to be engaged in services prior
to the pandemic than BIPOC PWUO. Fears about going
to hospitals and clinics during the pandemic may have
prevented many PWUO from initiating treatment. However, there was also signs of hope as those who received
a MOUD were more likely to complete their scheduled
healthcare visits and to pick up their medications even
while healthcare use overall declined. This suggests that
these services were perceived as vital to those receiving
them. As noted by experts previously, a crucial next step
to meeting this service gap involves ensuring technology
access and support for all groups of PWUO and ensuring low-threshold pathways for PWUO to access medication [31, 32].
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The ED emerged as a critical point for potential patient engagement, as rates of patients presenting in the
ED for overdose rose sharply during the pandemic. In
response to this shift, a bill was passed in December
2020 (East MAT Act, H.R. 2281) that allowed for providers without an X-waiver to provide up to a 72-h supply of buprenorphine to patients in acute opiate
withdrawal. Prior to this, patients were able to receive a
72-h supply if they returned to the ED for their daily
dose. In addition, as of April 28, 2021, all DEA licensed
providers are able to apply for an X-waiver without completing specific training as long as they are treating fewer
than 30 active patients at a time, thus further increasing
capacity for ED providers to serve as a site of initial patient engagement for initiating MAT [33].Incentivizing
ED physicians to become authorized to provide buprenorphine or allowing longer term prescriptions for
buprenorphine from the ED could be critical policy initiatives to ensure greater and faster entry into outpatient
treatment [34].
Telehealth was described as an important service
model to connect PWUO with buprenorphine treatment
during the emergence of COVID-19 [30]. Prior to
COVID-19, while the use of telehealth for substance use
disorders had increased 20 fold from 2010 to 2017, it
remained overall underutilized, as telehealth visits for
substance use disorders only made up 1.4% of all telehealth visits in 2017 [35]. Telehealth waivers from the
Centers for Medicare & Medicaid Services, expansion of
telehealth services through Federally Qualified Health
Centers and Rural Health Clinics and flexibility with
provision of telehealth services through applications not
fully compliant with HIPAA rules since COVID-19 have
made it easier for health care providers to deliver telehealth services [36]. Additionally, it relaxed requirements
for an in-person visit to initiate buprenorphine treatment, allowing for telehealth or telephone visits, which
should be allowed to continue post-pandemic as a
means of low-barrier access to care. However, challenges
in connecting patients and especially marginalized populations such as PWUO remain including access to adequate technology and internet access, especially in
persons living in transitional housing or homeless populations [31]. Future work should explore approaches to
address barriers to telehealth uptake among PWUO.
As demonstrated in this review, overdose continues to
be a growing consequence of opioid misuse, and racial
disparities that existed pre-pandemic are intensifying. In
June 2020, a Kaiser Family Foundation poll found that
13% of adults in the US reported increased substance
use due to COVID-19 related stress, and 40% of adults
reported symptoms of anxiety or depression, compared
to 10% in June 2019 [37]. Previous pre-pandemic literature pointed to depression and anxiety as associated with
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overdose risk in general populations [38], and more
prevalent in marginalized populations racial minorities
[38, 39].
In addition, the effects of structural racism that were
present prior to the pandemic were intensified as overdose disproportionately affected Black, Indigenous and
People of Color (BIPOC). BIPOC are less likely than
others to have access to healthcare in the US, and are
more likely to be arrested and incarcerated instead of receiving treatment for drug-related issues [40]. White
PWUO were more likely to be in treatment at the start
of the pandemic, and therefore were more likely to
maintain access to treatment. Increasing access to treatment for BIPOC could be accomplish through increasing
options for entering treatment (ED, primary care, telehealth), through culturally appropriate public health
campaigns, and increasing the diversity of the addiction
workforce [41]. Due to the ongoing nature of the pandemic, the unintended consequences of the COVID-19
pandemic on PWUO must be further studied, especially
for vulnerable subgroups, with a focus on developing actionable policy and clinical changes to improve healthcare delivery for this population.
Gaps in the literature

A comprehensive assessment of the consequences of the
pandemic on healthcare delivery for PWUO is not attainable with existing data. Most published data available
to inform practice and policy report on the first 3
months of the pandemic (see Fig. 3) with only two studies quantifying outcomes into Fall 2020. It is possible
that trends in overdose have further increased due to the
long-term nature of societal changes related to the pandemic, though this knowledge is lacking to date.
Further, all studies occurred in the US, highlighting an
important gap in the literature (see Fig. 3). The pandemic and OUD are both global crises, with waves occurring in synchronous patterns. Future research from
developing countries is important to describe and understand the global impact of these overlapping epidemics.
Finally, studies only described the dispensing and administration of buprenorphine and long-acting naltrexone.
Methadone is the most dispensed MOUD, yet it is not
represented in the evidence analyzed. The one study that
reported attendance at OTP visits did not distinguish between administration of methadone or buprenorphine
[17].
Limitations

Our review is limited by the gaps in the literature, as
outlined above. In addition, interpretation of findings is
limited due to challenges with disentangling changes in
healthcare delivery in the context of the COVID-19 pandemic due to the multiple confounding variables present

(2021) 16:60

Page 8 of 10

in society across multiple levels (fear to engage in public,
technology access gaps, loss of jobs, increased drug
tainting, etc). Importantly, we do not make the conclusion that the policy changes to OUD treatment delivery
caused the increases in ED visits or overdoses, rather we
describe the evidence with the intention of highlighting
trends and prompting future research. We also did not
include articles involving COVID-19-related illness in
PWUO as this has been reported elsewhere [11]. Although COVID-19 is reported to produce more serious
disease to individual health for PWUO it was outside the
scope of this review.

Conclusion
In this scoping review, we found that despite changes in
healthcare policy designed to increase access to MOUD
for PWUO, overdose related calls and deaths continued
to increase throughout the first months of the COVID19 pandemic. Further, racial minority populations were
disproportionately affected at higher rates by the intersection of COVID-19 and OUD. As the pandemic is ongoing, future research must focus on developing tailored
interventions to reduce morbidity and mortality for
PWUO, while addressing the needs of racial minorities.
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